Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (161-170 of 250) with videos related to

Pageof 25
Sort By:
Blood|August 9, 2014
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?María-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2014
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trialJosep-Maria Ribera, Albert Oriol, Mireia Morgades, et al.
Blood|October 27, 2015
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MMMaría-Victoria Mateos, Joaquín Martínez-López, Miguel-Teodoro Hernández, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2025
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation TrialsDavid F Moreno, Albert Oriol, Javier de la Rubia, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Blood|April 24, 2019
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only diseaseJuan-José Lahuerta, Ana Jiménez-Ubieto, Bruno Paiva, et al.
Blood|December 16, 2015
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysisBruno Paiva, María Victoria Mateos, Luis Ignacio Sanchez-Abarca, et al.
Leukemia & Lymphoma|January 9, 2014
Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patientsBlanca Xicoy, Josep-Maria Ribera, Markus Müller, et al.
Blood|July 14, 2012
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM studyLaura Rosiñol, Albert Oriol, Ana Isabel Teruel, et al.
The New England Journal of Medicine|February 24, 2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNikhil C Munshi, Larry D Anderson, Nina Shah, et al.
Pageof 25

Showing results (161-170 of 250) with videos related to

Sort By:
Pageof 25
Blood|August 9, 2014
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?María-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2014
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trialJosep-Maria Ribera, Albert Oriol, Mireia Morgades, et al.
Blood|October 27, 2015
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MMMaría-Victoria Mateos, Joaquín Martínez-López, Miguel-Teodoro Hernández, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2025
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation TrialsDavid F Moreno, Albert Oriol, Javier de la Rubia, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Blood|April 24, 2019
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only diseaseJuan-José Lahuerta, Ana Jiménez-Ubieto, Bruno Paiva, et al.
Blood|December 16, 2015
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysisBruno Paiva, María Victoria Mateos, Luis Ignacio Sanchez-Abarca, et al.
Leukemia & Lymphoma|January 9, 2014
Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patientsBlanca Xicoy, Josep-Maria Ribera, Markus Müller, et al.
Blood|July 14, 2012
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM studyLaura Rosiñol, Albert Oriol, Ana Isabel Teruel, et al.
The New England Journal of Medicine|February 24, 2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNikhil C Munshi, Larry D Anderson, Nina Shah, et al.
Pageof 25